Kymera Therapeutics Financials - Benzinga

Kymera Therapeutics Inc

KYMRNASDAQ

Trade with Public

Trade with Public

$111.95

-3.86-3.33%

In chiusura: Sep 25, 5:00 PM EST

$111.95

N/A

Post-mercato: 4:00 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Kymera Therapeutics Financials

Kymera Therapeutics (KYMR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share

Benzinga Newsdesk

PRO
Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 13.41 percent increase over losses of $(0.82) per share

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

Kymera Therapeutics Earnings Review: Q4 Summary

Benzinga Insights

PRO
Kymera Therapeutics Q4 EPS $(0.97) Misses $(0.78) Estimate, Sales $2.871M Miss $14.798M Estimate. Cash And Equivalents Of $1.6B

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.78) by 24.36 percent. This is a 10.23 percent decrease over losses of $(0.88) per share

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved